ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Protagonist Therapeutics Announces Fast Track Designation of Hepcidin Mimetic PTG-300
September 28, 2018Protagonist Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to therapeutic candidate PTG-300 for the treatment of chronic anemia due to ineffective erythropoiesis in patients with beta-thalassemia.
Pharma Sources Insight January 2025
